Financing and Funding Indian Healthcare: Navigating the Turbulent Tide
The cost of healthcare or, more appropriately, the cost a nation has to bear to provide healthcare to its citizens has been one of the most hotly debated issues globally. How one defines this paradigm is important: Is healthcare a right that citizens can demand from the state, or is the individual responsible for his/her own health? However, there is a general consensus that unless some form of universal health coverage care is available, the growth of the most robust economies can be derailed. The coverage should include access to preventive, promotive and curative care of sufficient quality to be effective while ensuring people do not suffer financial ruin.

One of the tectonic shifts in Indian healthcare has been the launch of ‘Ayushman Bharat’, which addresses both pillars of universal healthcare coverage—the role of primary care and financial access. Under the National Health Protection Scheme, the government plans to cover over 500 million population, making it one of the largest schemes on the planet. Traditionally, the public and private sectors have not worked together. International experience shows that the most efficient public healthcare systems use private capital and expertise to induce efficiency and innovation. The scheme gives a fresh impetus for both to work together towards achieving the nation’s goal of achieving universal healthcare.

A host of factors—ranging from price control to regulatory overreach and safety of the caregivers in hospitals—have threatened to derail the robust growth of the sector. However, we see this as an opportunity to relook at financing and funding, the regulatory framework and reimbursement mechanisms to build a new healthcare ecosystem.

The ‘New Indian Healthcare Ecosystem’ will redefine the healthcare delivery and products space with low-cost hospitals, speciality clinics, medical devices which cost a fraction of imported devices, mobile technologies which address primary healthcare needs and quality healthcare which is affordable. Besides addressing India’s needs, these innovations have the potential to be replicated in the developing world, where most issues mirror those in our country.

Rising patient consumerism, expansion of the continuum of care, a shift towards quality-based care, increasing patient participation, the use of technology in delivering care, and increasing insurance penetration are some of the disruptive trends which the Indian health economy is currently witnessing. These trends and turbulent events, along with the implementation of NHPS, present an opportunity for the relevant stakeholders to redefine and reorganise themselves and adopt new components of people, process and technology in their business models, in order to emerge successful in the ‘New Indian Health Economy’.
Section 1
Is India moving towards an equitable healthcare system?

Section 2
What were the effects of the turbulent events that hit the Indian healthcare industry last year?

Section 3
Can the National Health Protection Scheme (NHPS) be the inflexion point for the industry?

Section 4
Can the Indian healthcare industry continue to attract investors given its long-term potential?

Section 5
Are we now seeing the birth of a "New Indian Health Economy"?
# Section 1 — Is India moving towards an optimal healthcare system?

India is a microcosm of all the healthcare systems in the world.

<table>
<thead>
<tr>
<th>Healthcare models</th>
<th>Bismarck</th>
<th>Beveridge</th>
<th>Douglas model</th>
<th>Out of pocket</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Payer</strong></td>
<td><strong>Classic</strong></td>
<td><strong>Neoclassic</strong></td>
<td><strong>Classic</strong></td>
<td><strong>Neoclassic</strong></td>
</tr>
<tr>
<td>Private insurance</td>
<td>Private</td>
<td>Private and public insurance</td>
<td>Government</td>
<td>Government-run insurance</td>
</tr>
<tr>
<td><strong>Financing</strong></td>
<td>Citizen and employer premium</td>
<td>Citizen tax payments</td>
<td>Citizen premium</td>
<td>Citizen</td>
</tr>
<tr>
<td><strong>Provider</strong></td>
<td>Mostly private</td>
<td>Public</td>
<td>Mostly private</td>
<td>Mostly private</td>
</tr>
<tr>
<td><strong>Government’s role</strong></td>
<td>Regulation</td>
<td>Regulation and part-payment</td>
<td>Payment and delivery</td>
<td>Payment</td>
</tr>
<tr>
<td><strong>Price control</strong></td>
<td>Government manages prices through regulation</td>
<td>As the sole payer, govt. has strong control over prices</td>
<td>Government has limited control</td>
<td></td>
</tr>
<tr>
<td><strong>Examples</strong></td>
<td>Germany</td>
<td>Netherlands</td>
<td>Britain</td>
<td>Denmark</td>
</tr>
<tr>
<td>Austria</td>
<td>Czechia</td>
<td>Switzerland</td>
<td>Cuba</td>
<td>New Zealand</td>
</tr>
<tr>
<td>USA (mixed)</td>
<td>USA</td>
<td>Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Indian examples</strong></td>
<td>Individual/group insurance (private)</td>
<td>Public sector undertakings</td>
<td>State-run hospitals, armed forces</td>
<td>CGHS, PPPs</td>
</tr>
</tbody>
</table>

PwC Analysis
High-quality clinical outcomes at an affordable cost have helped project India as a medical hub.

The Indian healthcare system is moving towards quality healthcare at an affordable cost.

Joint Commission International (JCI)\(^1\) accredited hospitals and 513 National Accreditation Board for Hospitals & Healthcare Providers (NABH)\(^2\) accredited hospital

Cost of treatment is less than 1/10th in comparison to the USA\(^3\)

Clinical outcomes in leading hospitals are comparable to those of internationally recognised facilities

A strong brand of alternative medicine and rejuvenation therapies, along with an emphasis on wellness and prevention, has drawn patients from across the globe to the country.

Source: 1 - JCI website, 2 - NABH website, 3 – IBEF website, PwC analysis
A strong quality focus and clinical outcomes at a low cost, coupled with credibility in alternative medicine, have resulted in growing medical tourism in the country.

Around over half a million medical visas were issued in 2016. The number has increased at a CAGR of ~52% from 2014 to 2016.

Focus specialties for MVT in India

Cardiac sciences  Orthopaedics  Organ transplants  Neurosciences  Oncology  Bariatrics

Source: Ministry of Tourism, Government of India

A strong quality focus and clinical outcomes at a low cost, coupled with credibility in alternative medicine, have resulted in growing medical tourism in the country.

Source: PwC analysis MVT Medical Value Travel
India has a commitment to achieve Universal Health Coverage (UHC) [as part of Sustainable Development Goals]. However, its total healthcare expenditure is less than 5% of its GDP, which has resulted in sub optimal outcomes.

UHC tracer definition: UHC Tracer Index: Summary measure of coverage of essential health services, computed for each country by averaging service-coverage values across 16 tracer indicators on (i) reproductive, maternal, newborn and child health; (ii) infectious diseases; (iii) non-communicable diseases; and (iv) service capacity and access, and health security. A higher score reflects a higher access to these services.

Source: World Bank estimates, SDG Index and Dashboards Report 2017
OOPE: Out of Pocket Expenditure
High performing countries have used different methods for healthcare financing to achieve UHC.

High government spend

Czech Republic: 14% government, 85% out of pocket expenditure (OOPE)
Denmark: 13% government, 85% OOPE
Finland: 19% government, 78% OOPE
France: 7% government, 80% OOPE
Germany: 13% government, 77% OOPE
Italy: 22% government, 77% OOPE
Japan: 14% government, 84% OOPE
Belgium: 18% government, 78% OOPE
Netherlands: 5% government, 88% OOPE
New Zealand: 14% government, 82% OOPE
Canada: 13% government, 72% OOPE
Norway: 24% government, 83% OOPE
Spain: 24% government, 76% OOPE
Sweden: 14% government, 71% OOPE
Australia: 20% government, 85% OOPE
United Kingdom: 10% government, 70% OOPE

Average: 11% government, 58% OOPE

High government + out of pocket expenditure (OOPE)

Argentina: 31% government, 56% OOPE
Cyprus: 50% government, 46% OOPE
Singapore: 56% government, 42% OOPE
Switzerland: 25% government, 60% OOPE
Israel: 27% government, 62% OOPE
Hungary: 28% government, 68% OOPE
Ireland: 18% government, 68% OOPE
Portugal: 28% government, 67% OOPE
United States: 11% government, 50% OOPE

Average: 39% government, 58% OOPE

High government + prepaid spend

Czech Republic: 14% government, 85% prepaid
Denmark: 13% government, 85% prepaid
Finland: 19% government, 78% prepaid
France: 7% government, 80% prepaid
Germany: 13% government, 77% prepaid
Italy: 22% government, 77% prepaid
Japan: 14% government, 84% prepaid
Belgium: 18% government, 78% prepaid
Netherlands: 5% government, 88% prepaid
New Zealand: 14% government, 82% prepaid
Canada: 13% government, 72% prepaid
Norway: 24% government, 83% prepaid
Spain: 24% government, 76% prepaid
Sweden: 14% government, 71% prepaid
Australia: 20% government, 85% prepaid
United Kingdom: 10% government, 70% prepaid

Average: 11% government, 31% prepaid

The Nature of increased healthcare spend is important for better cost-efficient health outcomes.
In summary

• India is a microcosm of all the healthcare systems in the world given its multiple attributes, be it those of provider, payor or the role of the private sector and the government.

• The country is able to provide best quality outcomes at affordable price points, thus leading to a more than 50% annual growth in the issuance of medical visas for the last two years.

• However, significant challenges remain, especially related to healthcare expenditure, which is less than 5% of the GDP as compared to the world average of ~10%.

• This has impacted India’s stride towards UHC, with OOPE being above 60%.

• Countries which have performed relatively well on UHC generally have high government spending on healthcare.
Section 2

What were the effects of the turbulent events that hit the Indian healthcare industry last year?
## Impact of these events

<table>
<thead>
<tr>
<th>Event</th>
<th>What happened?</th>
<th>What was the impact?</th>
</tr>
</thead>
</table>
| **Price cap (stent and implant)*** | The National Pharmaceutical Pricing Authority (NPPA) fixed a price ceiling for stents in February 2017 (amendment in Feb 2018) and for knee implants in August 2017 | • **Significant reduction in stent and implant prices along with reduction in trade margins** (capped at 8%) for the entire distribution value chain (including hospital)  
• Companies **withdrew premium stents** from the Indian market.  
• Companies have **less inclination to launch new products** given the uncertainty in the regulatory scenario.  
• **Reverse medical tourism** with patients from India travelling to neighbouring countries for availing medical services. |
| **Demonetisation** | Circulation of high-denomination currency (500 and 1,000) was stopped in November 2016. | • Given the high OOPE expenditure, there were **liquidity issues** for cash paying patients. This made it difficult for patients to pay for acute **procedures/surgeries** and also led to **postponement of elective surgeries**.  
• **Hospitals and diagnostic centres saw reduction in revenue growth for a few months.** |
| **Attempts for fixing procedure rates** | Some states (West Bengal** and Karnataka**) have attempted to regulate and fix procedure rates. | • **Cap on procedure rates** could make it difficult for hospitals to provide quality services.  
• Lower profitability due to this capping can impact **new hospital investments.**  
• **Possibility of other states also bringing in similar bills** with an aim to cater to populist sentiments. |
| **Other regulatory issues** | Hospitals were penalised and licences were cancelled on account of 1-2 unfortunate incidents. | • A few hospitals were **forced to curtail operations** (hospital licence cancelled, removal from government empanelment, suspension of operations for a few departments) for a brief period. This resulted in revenue loss and negatively impacted the hospital’s image.  
• Patients could not avail/had to postpone treatment or look for alternative options.  
• Anxiety and job security concern for employees  
• **Question of propriety** – should the patients, employees and the organisation suffer due to an individual’s mistake or error? |

Source: *NPPA, **West Bengal Clinical Establishment Regulatory Commission, the West Bengal Clinical Establishments Registration, Regulation and Transparency Bill, 2017, and the Karnataka Private Medical Establishments (Amendment) Bill, 2017, Newspaper articles  
UHC – Universal Health Coverage
What needs to be done?

While one of the events (demonetisation) was a one-off event, they nevertheless signal a need for change:

- There is a strong need for increasing transparency, improving hospital and patient connect, and dispelling the negative perception of the industry.
- With the aim of balancing the need for returns for investors and affordability for patients, there is a need for hospitals to look at their cost structure and work on operational efficiency programmes.
- Technology advancements elements such as AI, wearables and other mobile technologies, along with IoT, can play a big role in delivering quality and affordable care.
- The government also needs to use this opportunity to create a robust regulatory framework keeping in mind the interest of all stakeholders.
- There is a need for all the stakeholders to join hands and create standard treatment protocols and SOPs which will help improve transparency and trust.
- While all the above measures will help, the major issue remains the high OOPE. Effective implementation of NHPS and UHC could solve this problem.
### Section 3 — Can NHPS be the inflexion point for the industry?

World's largest non-contributory government-sponsored health insurance scheme

#### Features of scheme

<table>
<thead>
<tr>
<th>Feature</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>0.5 billion</strong></td>
<td>beneficiaries</td>
</tr>
<tr>
<td>Beneficiary identification as per</td>
<td><em>Socio Economic Census 2011</em></td>
</tr>
<tr>
<td>Proposed Aadhaar linkage</td>
<td></td>
</tr>
<tr>
<td><strong>5,00,000 INR</strong></td>
<td>family floater cap</td>
</tr>
<tr>
<td>Premium to be borne</td>
<td><strong>60:40</strong> by Centre and state</td>
</tr>
<tr>
<td>Additional source of funding for government:</td>
<td><strong>1% cess</strong></td>
</tr>
<tr>
<td>New institutional structures proposed –</td>
<td><em>National Health Agency</em> and <em>State Health Agency</em></td>
</tr>
<tr>
<td>Both public and private hospitals to be empanelled</td>
<td></td>
</tr>
<tr>
<td>Focused on the most vulnerable population</td>
<td></td>
</tr>
</tbody>
</table>

#### Paradigm shifts

<table>
<thead>
<tr>
<th>Shift</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shift towards output-based strategic purchasing of services from private sector</td>
<td></td>
</tr>
<tr>
<td>Merger of different government insurance schemes</td>
<td></td>
</tr>
<tr>
<td>Government shifts from being a provider to a payer also</td>
<td></td>
</tr>
</tbody>
</table>
How will the NHPS evolve?

**Short-term steps**
- Set up governance mechanism
- Increase hospital empanelment
- Define the benefits under the scheme

**Medium-term steps**
- Price discovery and financing
- Right targeting of beneficiaries
- Expand scheme coverage
- Merge different schemes

**Long-term steps**
- Benefits under the scheme to include OPD and Primary care
- Build in system efficiencies

**Stakeholder Implications**

<table>
<thead>
<tr>
<th>Hospitals</th>
<th>Pharmaceuticals and diagnostic companies</th>
<th>Insurance companies</th>
<th>Digital and IT service providers</th>
<th>Central and state government and sector regulators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Push for package rates</td>
<td>Focus on low-cost drugs and quality</td>
<td>Build capacities to handle large claims and identify frauds, abuse and misuse</td>
<td>Develop IT architecture to link patient data, hospital data and insurance company data with Socio Economic Classification (SEC) and Aadhaar data</td>
<td>Identify sources of financing</td>
</tr>
<tr>
<td>Focus on quality</td>
<td>Focus on centralised procurement</td>
<td>Empanel hospitals in tier 2 and 3 areas</td>
<td></td>
<td>Build in system automation for monitoring and grievance redressal</td>
</tr>
<tr>
<td>Focus on accreditation</td>
<td>Focus on supply-side shortages</td>
<td>Negotiate package rates</td>
<td></td>
<td>Ensure fair competition</td>
</tr>
</tbody>
</table>
Current ecosystem

Hospitals

Hospital empanelment: <35,000 hospitals under ROHINI, majority in tier 1 and 2 cities

Package rate: <150 procedures under GIPSA package

People insured: 33.5 crore persons under government-sponsored health insurance, including RSBY

OOPE: >60% of THE is OOPE. Limited coverage of pre-and post-hospitalisation expenses.

Hospital fraud: ~15% of all claims are fraudulent claims

Hospital payment: >25% of claims (in terms of value) are settled after one month

State government

Different schemes like RSBY and other insurance schemes

ROHINI – Registry of Hospitals in Network on Insurance, GIPSA – General Insurers’ Public Sector Association (India), RSBY - Rashtriya Swasthya Bima Yojana, TPA – Third party administrator, THE – Total health expenditure

Future ecosystem

- Hospitals
  - Increased focus on quality (NABH) and treatment protocols/standards
  - Technology to act as a unifying force
  - Increase in number of hospitals empanelled especially in lower order cities and rural areas
- Patients
  - Increase in number of procedures under package rates
  - Increase in patient number and claim cases
- State government
  - Merge different Schemes
  - 50 crore people, instant claim settlement, empanel public hospitals, package rates, quality, hospitals empanelled
  - Benefit package to include multiple inpatient department (IPD) care procedures along with pre- and post-hospitalisation charges
- Insurance companies/TPAs
  - Improve system efficiencies and capacities
  - Decrease in number of fraudulent cases for viability
  - Push for instant claim settlement driven by Aadhaar and use of technology
  - Improve system efficiencies and capacities

State government

- Increase in number of hospitals empanelled especially in lower order cities and rural areas
- Increase in number of procedures under package rates
- Technology to act as a unifying force
- Merge different Schemes
- 50 crore people, instant claim settlement, empanel public hospitals, package rates, quality, hospitals empanelled
- Benefit package to include multiple inpatient department (IPD) care procedures along with pre- and post-hospitalisation charges
- Improve system efficiencies and capacities
- Decrease in number of fraudulent cases for viability
- Push for instant claim settlement driven by Aadhaar and use of technology
Most of the leading hospital chains have shown steady revenue growth despite the recent headwinds.

Revenue growth of the leading hospital chains in the country

<table>
<thead>
<tr>
<th>Chain</th>
<th>9M FY17 over 9M FY 16</th>
<th>9M FY18 over 9M FY 17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fortis Healthcare*</td>
<td>9%</td>
<td>1%</td>
</tr>
<tr>
<td>Apollo Hospitals*</td>
<td>12%</td>
<td>11%</td>
</tr>
<tr>
<td>Narayana Health</td>
<td>18%</td>
<td>17%</td>
</tr>
<tr>
<td>HCG</td>
<td>21%</td>
<td>18%</td>
</tr>
<tr>
<td>Max*</td>
<td>23%</td>
<td>9%</td>
</tr>
<tr>
<td>Shalby Hospitals</td>
<td>17%</td>
<td></td>
</tr>
</tbody>
</table>

*Only the hospital business revenue is accounted for in these cases.
Source: Q3 Earning updates for FY17 and FY18 from company websites – Apollo, Fortis, Narayana Health, HCG, Max and Shalby Hospitals.
Healthcare Players continue to see listing as an attractive option for raising funds

<table>
<thead>
<tr>
<th>Year</th>
<th>Company</th>
<th>Amount raised (crore INR)</th>
<th>At an approx. valuation (crore INR)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Healthcare IPOs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shalby Hospitals</td>
<td>504.8</td>
<td>2,678</td>
</tr>
<tr>
<td></td>
<td>Aster DM Healthcare</td>
<td>725</td>
<td>9,600</td>
</tr>
<tr>
<td></td>
<td><strong>FY17</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thyrocare</td>
<td>482</td>
<td>2,412</td>
</tr>
<tr>
<td></td>
<td><strong>FY16</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Narayana Health</td>
<td>613</td>
<td>5,109</td>
</tr>
<tr>
<td></td>
<td>HCG</td>
<td>650</td>
<td>1,854</td>
</tr>
<tr>
<td></td>
<td>Dr. Lal Pathlabs</td>
<td>670</td>
<td>4,500</td>
</tr>
</tbody>
</table>

Source: VCCircle and Livemint website

Like FY 16 and FY 17, FY 18 also witnessed continued investor interest in healthcare IPOs, with Shalby and Aster DM getting listed.
The interest of the private equity fraternity continued in the year 2017 with multiple companies in the healthcare sector raising funds. This year also saw private equity interest in the home healthcare space.

<table>
<thead>
<tr>
<th>Company</th>
<th>Amount (million USD)</th>
<th>Sector</th>
<th>Investors</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiant Life Care</td>
<td>200</td>
<td>Hospitals</td>
<td>KKR</td>
<td>July '17</td>
</tr>
<tr>
<td>Condis Healthcare</td>
<td>200</td>
<td>Hospitals</td>
<td>India Value Fund</td>
<td>Mar '17</td>
</tr>
<tr>
<td>Manipal Health Enterprises</td>
<td>171</td>
<td>Hospitals</td>
<td>Temasek</td>
<td>Mar '17</td>
</tr>
<tr>
<td>Max Healthcare Institute</td>
<td>75</td>
<td>Hospitals</td>
<td>IFC</td>
<td>May '17</td>
</tr>
<tr>
<td>Paras Healthcare</td>
<td>43</td>
<td>Hospitals</td>
<td>Creador Capital</td>
<td>July '17</td>
</tr>
<tr>
<td>Healthcare at Home</td>
<td>40</td>
<td>Home healthcare services</td>
<td>Quadria India</td>
<td>Apr '17</td>
</tr>
<tr>
<td>Portea Medical</td>
<td>26</td>
<td>Home healthcare services</td>
<td>IFC, Accel India, Sabre Capital, Qualcomm Ventures, CDC-MEMG</td>
<td>Nov '17</td>
</tr>
<tr>
<td>Asian Institute of Medical Sciences</td>
<td>21</td>
<td>Hospitals</td>
<td>CDC Group</td>
<td>Dec '17</td>
</tr>
<tr>
<td>Nightingales Home Health Services</td>
<td>21</td>
<td>Home healthcare services</td>
<td>Eight Roads Ventures, Mahindra Partners</td>
<td>Apr '17</td>
</tr>
<tr>
<td>iGenetic Diagnostics</td>
<td>20</td>
<td>Diagnostics</td>
<td>CDC-MEMG</td>
<td>Mar '17</td>
</tr>
<tr>
<td>Regency Hospital</td>
<td>14</td>
<td>Hospitals</td>
<td>IFC, Healthquad, Kois Invest</td>
<td>Feb '17</td>
</tr>
<tr>
<td>ASG Eye Hospitals</td>
<td>11.7</td>
<td>Eye Care</td>
<td>IDFC Alternatives</td>
<td>Sep '17</td>
</tr>
</tbody>
</table>

Source: Venture Intelligence

PwC analysis
Healthcare has seen a significant increase in FDI inflow over the last 4 years.

Healthcare FDI inflows (million USD)

<table>
<thead>
<tr>
<th>Year</th>
<th>FDI inflow (million USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY11</td>
<td>240</td>
</tr>
<tr>
<td>FY12</td>
<td>318</td>
</tr>
<tr>
<td>FY13</td>
<td>257</td>
</tr>
<tr>
<td>FY14</td>
<td>685</td>
</tr>
<tr>
<td>FY15</td>
<td>663</td>
</tr>
<tr>
<td>FY16</td>
<td>647</td>
</tr>
<tr>
<td>FY17</td>
<td>747</td>
</tr>
</tbody>
</table>

Source: FDI Fact Sheets

In summary

- Most of the leading hospital chains have shown steady revenue growth despite the recent headwinds.
- FY18 continued to witness interest from the primary market in healthcare companies, with the listing of Shalby Hospital and Aster DM Healthcare.
- The interest of the PE fraternity continued in the year 2017, with investment taking place in multiple healthcare companies.
- FDI flow continued unabated with a flow of 747 million USD in FY17, the highest amount in the last 7 years.
Section 5

“Are we now seeing the birth of a “New Indian Health Economy”?”
To grow in this “New Indian Health Economy”, stakeholders need to focus on creating value in the ecosystem.

An ecosystem of collaborators with interrelated value drivers

- Renewed focus on generics
- Healthcare trackers and wearables

Pharmaceuticals and life sciences

- Shift from sickness to wellness
- Operational efficiency
- Better quality at lower cost
- Physician engagement model

Healthcare providers

- Rise in consumerism
- Enhanced customer/patient experience
- Tailored health plan

Insurance companies

- Digital health
- Integration with telecom
- Artificial intelligence
- Robotics

- Increase insurance penetration
- Focus on quality outcomes
- Decrease frauds

- NHPS implementation
- Effective finance mechanism

Continuum of care

- Low cost

- Physician engagement model

Government

- Increase insurance penetration
- Focus on quality outcomes
- Decrease frauds

Hospital provider

- Rise in consumerism
- Enhanced customer/patient experience
- Tailored health plan

Consumer

- Digital health
- Integration with telecom
- Artificial intelligence
- Robotics

Technology players

- NHPS implementation
- Effective finance mechanism

- Quality outcomes

- Care transparency

- Technology as lever
To grow in this ‘New Health Economy’, stakeholders need to align themselves with the accelerating trends.

New Indian Health Economy

- **Shift from volume to value**
- **Care delivery**
- **Rise of consumerism**
- **From sick**
- **Wellness**
- **Decentralisation**
- **From**
- **To well**
- **Diagnostics and therapeutics**
- **Surge in interest in wellness**
- **Platform and support**
- **Financing, payment and regulation**
- **Government**
  - Focus on moving from provider to payor
  - Effective implementation of NHPS
  - Renewed focus on generics
  - Facilitate ‘Make in India’
- **Providers**
  - Providers need to recalibrate their operating model
  - Leverage the following:
    - Technology
    - Value-based care
    - Operational efficiency
    - Patient experience
About NATHEALTH

NATHEALTH has been created with the Vision to “Be the credible and unified voice in improving access and quality of healthcare”. Leading Healthcare Service Providers, Medical Technology Providers (Devices, Equipments & IT), Diagnostic Service Providers, Health Insurance companies, Health Education Institutions, Medical Journalism companies, Biotech/Lifesciences related companies, Healthcare Publishers, Healthcare Consultants, Home Healthcare companies, PE & VC companies and other stakeholders have come together to build NATHEALTH as a common platform to create the next level of momentum in Indian Healthcare. NATHEALTH is an inclusive Institution that has representation of small & medium hospitals and nursing homes as well as Healthcare Start-up companies. NATHEALTH is committed to work on its Mission to encourage innovation, help bridge the skill and capacity gap, help shape policy & regulations and enable the environment to fund long term growth. NATHEALTH aims to help build a better and healthier future for both rural and urban India.

Contact

Mr. Anjan Bose
Secretary General, Healthcare Federation of India (NATHEALTH)
Mb: +91-9999016000
anjan.bose@nathealth.co.in

About PwC’s Healthcare practice

PwC India’s Healthcare team offers advisory services in the healthcare sector covering multiple domains such as strategy, business planning, market scan, commercial due diligence, feasibility study, operations improvement, cost reduction, health IT, digital and technology, internal audit and PPPs.

Healthcare Advisory has a dedicated team with diverse operational experience in setting up and managing hospitals, and in healthcare consulting. This enables the team to deliver granular strategy and market and operational insights of the highest quality. The team works with leading healthcare providers, medical technology companies, central and state governments, diagnostic players, insurance companies and private equity players on projects both in India and overseas.

Contact

Dr. Rana Mehta
Partner and Leader, Healthcare
PricewaterhouseCoopers Private Limited
D: +91 124 6266710 | M: +91 9910511577
rana.mehta@pwc.com
About PwC

At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 157 countries with more than 2,23,000 people who are committed to delivering quality in assurance, advisory and tax services. Find out more and tell us what matters to you by visiting us at www.pwc.com

In India, PwC has offices in these cities: Ahmedabad, Bengaluru, Chennai, Delhi NCR, Hyderabad, Kolkata, Mumbai and Pune. For more information about PwC India’s service offerings, visit www.pwc.com/in

PwC refers to the PwC International network and/or one or more of its member firms, each of which is a separate, independent and distinct legal entity in separate lines of service. Please see www.pwc.com/structure for further details.

©2018 PwC. All rights reserved.

Acknowledgements

Healthcare Team
Dr. Preet Matani
Ashish Rampuria
Dr. Ashwani Aggarwal
Varun Karwa
Dr. Kuntal Mukherjee

Publishing and Online Team
Dion D'Souza

Corporate Communications Team
Kirtika Saxena